Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.07
AKRX's Cash to Debt is ranked lower than
55% of the 1173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. AKRX: 0.07 )
AKRX' s 10-Year Cash to Debt Range
Min: 0   Max: N/A
Current: 0.07

Equity to Asset 0.20
AKRX's Equity to Asset is ranked lower than
52% of the 983 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. AKRX: 0.20 )
AKRX' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.86
Current: 0.2

0.18
0.86
F-Score: 4
Z-Score: 2.62
M-Score: -0.92
WACC vs ROIC
7.30%
6.82%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 16.31
AKRX's Operating margin (%) is ranked higher than
86% of the 1117 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. AKRX: 16.31 )
AKRX' s 10-Year Operating margin (%) Range
Min: -50.73   Max: 27.76
Current: 16.31

-50.73
27.76
Net-margin (%) 5.96
AKRX's Net-margin (%) is ranked higher than
72% of the 1117 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.55 vs. AKRX: 5.96 )
AKRX' s 10-Year Net-margin (%) Range
Min: -36.46   Max: 31.41
Current: 5.96

-36.46
31.41
ROE (%) 11.59
AKRX's ROE (%) is ranked higher than
80% of the 1157 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.46 vs. AKRX: 11.59 )
AKRX' s 10-Year ROE (%) Range
Min: -108.38   Max: 35.12
Current: 11.59

-108.38
35.12
ROA (%) 3.00
AKRX's ROA (%) is ranked higher than
71% of the 1183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.53 vs. AKRX: 3.00 )
AKRX' s 10-Year ROA (%) Range
Min: -33.5   Max: 24.27
Current: 3

-33.5
24.27
ROC (Joel Greenblatt) (%) 33.65
AKRX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 1178 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.83 vs. AKRX: 33.65 )
AKRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -41.62   Max: 56.75
Current: 33.65

-41.62
56.75
Revenue Growth (3Y)(%) 54.00
AKRX's Revenue Growth (3Y)(%) is ranked higher than
98% of the 971 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. AKRX: 54.00 )
AKRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -37   Max: 54
Current: 54

-37
54
EBITDA Growth (3Y)(%) 37.00
AKRX's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. AKRX: 37.00 )
AKRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.1   Max: 171.4
Current: 37

-67.1
171.4
EPS Growth (3Y)(%) -6.00
AKRX's EPS Growth (3Y)(%) is ranked higher than
66% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. AKRX: -6.00 )
AKRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.4   Max: 93.1
Current: -6

-50.4
93.1
» AKRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AKRX Guru Trades in Q2 2014

Columbia Wanger 8,123,700 sh (+12.58%)
Jim Simons Sold Out
Pioneer Investments 254,698 sh (-14.49%)
Murray Stahl 26,464 sh (-24.76%)
Mario Gabelli 9,950 sh (-37.42%)
Joel Greenblatt 39,285 sh (-42.33%)
» More
Q3 2014

AKRX Guru Trades in Q3 2014

Steven Cohen 49,100 sh (New)
Paul Tudor Jones 14,400 sh (New)
Pioneer Investments 213,151 sh (unchged)
Mario Gabelli 9,300 sh (-6.53%)
Murray Stahl 23,011 sh (-13.05%)
Columbia Wanger 6,846,275 sh (-15.72%)
Joel Greenblatt 24,479 sh (-37.69%)
» More
Q4 2014

AKRX Guru Trades in Q4 2014

Steven Cohen 121,600 sh (+147.66%)
Joel Greenblatt 26,536 sh (+8.40%)
Pioneer Investments Sold Out
Paul Tudor Jones 14,300 sh (-0.69%)
Murray Stahl 22,606 sh (-1.76%)
Columbia Wanger 6,524,486 sh (-4.70%)
Mario Gabelli 7,500 sh (-19.35%)
» More
Q1 2015

AKRX Guru Trades in Q1 2015

George Soros 15,500 sh (New)
Louis Moore Bacon 70,000 sh (New)
Paul Tudor Jones 27,977 sh (+95.64%)
Mario Gabelli 13,000 sh (+73.33%)
Steven Cohen 196,200 sh (+61.35%)
Joel Greenblatt 35,233 sh (+32.77%)
Murray Stahl 17,721 sh (-21.61%)
Columbia Wanger 4,209,486 sh (-35.48%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 182.80
AKRX's P/E(ttm) is ranked higher than
63% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.60 vs. AKRX: 182.80 )
AKRX' s 10-Year P/E(ttm) Range
Min: 13.23   Max: 337.5
Current: 182.8

13.23
337.5
Forward P/E 18.48
AKRX's Forward P/E is ranked higher than
85% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AKRX: 18.48 )
N/A
PE(NRI) 169.90
AKRX's PE(NRI) is ranked higher than
68% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 57.50 vs. AKRX: 169.90 )
AKRX' s 10-Year PE(NRI) Range
Min: 13.17   Max: 318.21
Current: 169.9

13.17
318.21
P/B 12.40
AKRX's P/B is ranked lower than
58% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. AKRX: 12.40 )
AKRX' s 10-Year P/B Range
Min: 1.42   Max: 41.45
Current: 12.4

1.42
41.45
P/S 9.10
AKRX's P/S is ranked lower than
61% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. AKRX: 9.10 )
AKRX' s 10-Year P/S Range
Min: 0.76   Max: 12.87
Current: 9.1

0.76
12.87
POCF 176.96
AKRX's POCF is ranked higher than
68% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.21 vs. AKRX: 176.96 )
AKRX' s 10-Year POCF Range
Min: 23.75   Max: 230.17
Current: 176.96

23.75
230.17
EV-to-EBIT 61.10
AKRX's EV-to-EBIT is ranked higher than
71% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.19 vs. AKRX: 61.10 )
AKRX' s 10-Year EV-to-EBIT Range
Min: -430.4   Max: 114.3
Current: 61.1

-430.4
114.3
Shiller P/E 196.70
AKRX's Shiller P/E is ranked higher than
71% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AKRX: 196.70 )
AKRX' s 10-Year Shiller P/E Range
Min: 110.53   Max: 728
Current: 196.7

110.53
728
Current Ratio 3.68
AKRX's Current Ratio is ranked higher than
82% of the 1051 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. AKRX: 3.68 )
AKRX' s 10-Year Current Ratio Range
Min: 0.3   Max: 5.51
Current: 3.68

0.3
5.51
Quick Ratio 2.71
AKRX's Quick Ratio is ranked higher than
81% of the 1051 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. AKRX: 2.71 )
AKRX' s 10-Year Quick Ratio Range
Min: 0.06   Max: 4.26
Current: 2.71

0.06
4.26
Days Inventory 121.31
AKRX's Days Inventory is ranked higher than
75% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 145.57 vs. AKRX: 121.31 )
AKRX' s 10-Year Days Inventory Range
Min: 42.24   Max: 188.37
Current: 121.31

42.24
188.37
Days Sales Outstanding 135.84
AKRX's Days Sales Outstanding is ranked higher than
62% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 91.38 vs. AKRX: 135.84 )
AKRX' s 10-Year Days Sales Outstanding Range
Min: 10.09   Max: 135.84
Current: 135.84

10.09
135.84

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 13.30
AKRX's Price/DCF (Projected) is ranked higher than
69% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. AKRX: 13.30 )
AKRX' s 10-Year Price/DCF (Projected) Range
Min: 8.35   Max: 50.58
Current: 13.3

8.35
50.58
Price/Median PS Value 1.50
AKRX's Price/Median PS Value is ranked higher than
78% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. AKRX: 1.50 )
AKRX' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 1.99
Current: 1.5

0.08
1.99
Earnings Yield (Greenblatt) 1.60
AKRX's Earnings Yield (Greenblatt) is ranked higher than
64% of the 1170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. AKRX: 1.60 )
AKRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 5.3
Current: 1.6

0.9
5.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:FDA.Germany,
Akorn Inc is a Louisiana corporation founded in 1971 in Abita Springs, Louisiana. The Company manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals. In addition, it has markets and distributes vaccines purchased from outside sources. It operates pharmaceutical manufacturing facilities in Decatur, Illinois and Somerset, New Jersey, and in Paonta Sahib, Himachal Pradesh, India. It also operates a Research and Development center in Vernon Hills, Illinois and a distribution warehouse in Gurnee, Illinois. Its three operating segments are: ophthalmic; hospital drugs & injectables; contract services. Ophthalmic Segment: It markets a full line of diagnostic and therapeutic ophthalmic pharmaceutical products. Diagnostic products, primarily used in the office setting, include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes and others. Therapeutic products, sold primarily to wholesalers, chain drug stores and other national account customers, include antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications. Non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments and eyelid cleansers. Hospital Drugs & Injectables Segment - it markets a line of niche hospital drug and injectable pharmaceutical products, including antidotes, anti-infectives, and controlled substances for pain management and anesthesia, and other selected pharmaceutical products. These products are predominately sold to hospitals through the wholesale distribution channel. The Companys customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. The Company targets products with limited competition due to difficulty in manufacturing and/or the products market size. Contract Services Segment: It manufactures ophthalmic and injectable pharmaceutical products for third party pharmaceutical customers based on their specifications. The Company is competitors for hospital drugs & injectables segment include both generic and name brand companies such as Hospira, Inc., Teva Pharmaceutical Industries, Pfizer, Sagent Pharmaceuticals, Novartis, Fresenius-Kabi, Daiichi Sankyo, and Hikma. For ophthalmic segment its competitors include, Allergan Pharmaceuticals, Inc., Novartis, Valeant Pharmaceuticals International, Inc., Apotex and Sun Pharmaceuticals, among others.
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
Analysts Disagree Over Significance of Akorn, Inc’s Financial Errors Apr 28 2015 
Weekly CEO Sells Highlight: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic Packag Aug 09 2014 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 
Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL Sep 24 2012 
5 Healthcare Picks for 2012 Mar 21 2012 
Weekly CFO Sells Highlight: AN, CATM, AKRX, NNN, FTNT Aug 28 2011 
Akorn Inc. (AKRX) CFO Timothy A Dick buys 3,900 Shares Aug 16 2010 
Akorn Inc. Reports Operating Results (10-Q) May 10 2010 
Akorn Inc. Reports Operating Results (10-Q) Nov 09 2009 
Weekly CFO Buy Highlights: Gigatronics Inc., Akorn Inc., MainSource Financial Group Inc, U.S. Auto P Sep 06 2009 

More From Other Websites
AKORN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... May 20 2015
Celgene, Lannett Lead Boisterous Day For Drugmakers May 18 2015
AKORN INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or... May 18 2015
Akorn Receives NASDAQ Delinquency Notice May 18 2015
Pharmaceutical firm wants lethal injection drugs returned May 06 2015
Pharmaceutical firm wants lethal injection drugs returned May 06 2015
Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Akorn, Inc. May 04 2015
Law Offices of Howard G. Smith Reminds Investors Of Today’s Lead Plaintiff Deadline, May 4, 2015,... May 04 2015
10-K for Akorn, Inc. May 03 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Akorn,... May 01 2015
Oklahoma will not say if it has returned lethal injection drug May 01 2015
Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action... May 01 2015
Manufacturer asks Oklahoma to return any execution drugs Apr 30 2015
Manufacturer asks Oklahoma to return any execution drugs Apr 30 2015
Investor Alert: Holzer & Holzer Announces Class Action Filed on Behalf of Investors in Akorn, Inc.;... Apr 30 2015
AKORN, INC. SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Update to Shareholder... Apr 30 2015
AKORN ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Potential... Apr 30 2015
AKRX Investor Alert: Law Offices of Howard G. Smith Announces That a Class Action Has Been Filed on... Apr 30 2015
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Pendency of Class... Apr 29 2015
Law Offices of Howard G. Smith Investigates Claims On Behalf Of Akorn, Inc. Investors Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK